Editor's Note Findings from The ARRC II study show using advanced recovery room care (ARRC) for medium-risk surgical patients significantly reduces 18-month postoperative mortality compared to standard ward care. As detailed in a December 11 research letter in JAMA Surgery, this benefit appears linked to minimizing early postoperative complications, which…

Read More

Editor's Note Balloon catheters for atrial fibrillation patients and implantable radiographic markers were the subjects of separate US Food and Drug Administration (FDA) Class 1 recalls—the most severe category indicating risk of serious injury or death—announced on December 18. The first recall involves Boston Scientific’s POLARx Cryoablation devices. Higher-than-anticipated reports…

Read More

Editor's Note Risk of delayed therapy and death related to Ivenix large-volume infusion pumps is prompting supplier Fresenius Kabi USA to pull a subset of the devices from the market, according to an early alert from The US Food and Drug Administration (FDA). Issued December 11, the early alert is…

Read More

Editor's Note A study analyzing data from 124,577 suspected sepsis cases across 236 US hospitals found that antibiotic de-escalation—switching to narrower-spectrum antibiotics or stopping broad-spectrum antibiotics—occurred in less than 30% of cases but was associated with improved patient outcomes, according to December 6 report from the Center for Infectious Disease…

Read More

Editor's Note The US Food and Drug Administration (FDA) designated Cardinal health’s recall of certain lots of the Monoject U-100 1 mL Syringe Luer-Lock with Tip Cap Soft Pack a Class 1, the most severe recall category indicating serious risk of injury or death. The product is designed to administer…

Read More

Editor's Note The US Food and Drug Administration (FDA) has designated Class 1 recalls—the most severe category indicating risk of serious injury or death—involving three systems: Atlan anesthesia workstations from Draeger, CADD-Solis ambulatory infusion pumps from Smiths Medical, and Trilogy Evo ventilators from Philips Respironics. FDA issued all three announcements…

Read More

Editor's Note Adverse events (AEs) remain widespread in perioperative care, affecting nearly one in three patients and resulting in substantial and often preventable patient harm, according to a retrospective cohort study published November 13 in The BMJ. The study analyzed 1,009 weighted admissions from a sample of 64,121 surgical patients…

Read More

Editor's Note Survival rates following out-of-hospital cardiac arrest (OHCA) have not returned to pre-pandemic levels and continue to reflect racial disparities, according to a preliminary study set for presentation at the American Heart Association’s Scientific Sessions 2024. Analyzing data from over half a million U.S. adults who experienced OHCA between…

Read More

Editor's Note Critical care bed availability influences whether patients are admitted to intensive care after surgery, but it does not significantly affect postoperative outcomes, according to a study published September 25 in the journal Anaesthesia. The study involved 19,491 surgical patients from 248 hospitals in the UK, Australia, and New…

Read More

Editor's Note The US Food and Drug Administration (FDA) designated software-related recalls for Fresenius Kabi USA’s Iveni Infusion Systems and Philips Respironics Triology Evo ventilators as class 1, the most severe category indicating serious risk of injury or death. According to FDA’s October 1 announcement, Fresenius recalled the Ivenix Infusion…

Read More